Whitehawk Therapeutics adds Vijay Iyengar to board of directors
The clinical-stage oncology company named the former Incyte executive as a Class III director effective September 9, 2026.
SEC filing
Latest
11 stories
Wednesday, September 16
Friday, September 11
Incyte posts terminated Phase 1 KRASG12C combo results; registers new INCB161734 mass balance study
Thursday, September 10
Tuesday, September 1
Incyte registers Phase 3 MAESTRA 3 trial in cyclin E1-overexpressing ovarian cancer
Monday, August 24
Incyte-backed trials: OSU tests pemigatinib cycling regimen; OHSU starts Opzelura pilot for PG
Oruka Therapeutics names Todd Edwards as Chief Commercial Officer
Edwards, a former Arcutis and Incyte dermatology commercial leader, joined Oruka on August 24, 2026 with a base salary, bonus target, equity grants, and a signing bonus.
SEC filing
Monday, August 17
Incyte posts results for Phase 1/2 anti-PD-1, LAG-3, TIM-3 combo trial in advanced malignancies
Friday, August 14
Incyte-linked filings this week: FIGHT-302 results posted, new academic pancreatic trial listed
Tuesday, July 28
Incyte raises 2026 sales guidance, adds ten data readouts, closes Vega deal
The company lifted full-year net sales and expense guidance and outlined ten clinical readouts for the second half of 2026, including four registrational trials.
SEC filing